Please use this identifier to cite or link to this item:
|Title:||Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial|
De Azambuja, Evandro
Dueck, Amylou C.
et al, .
Zujewski, Jo Anne
Northern Clinical School: Medicine
|Publisher:||American Society of Clinical Oncology|
|Citation:||Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial, Journal of Clinical Oncology, vol.34, 10, 2016,pp 1034-1042|
|Department/Unit/Centre:||Northern Clinical School: Medicine|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.